MedBulletinsAura Celeste
Pediatrics

Monthly pediatrics bulletin — September 18, 2026

🎧 Listen to this issueAudio newscast · 6:22 min

MONTHLY PEDIATRICS BULLETIN — September 18, 2026
Period covered: August 19 – September 18, 2026.

Neonatology and perinatal

1. Four in five deaths (stillbirths, neonates and children under 5) would be preventable: eight years of CHAMPS surveillance in seven countries

[Epidemiology] [Sub-Saharan Africa and South Asia; CDC/MMWR]
On September 10, MMWR Surveillance Summaries published results from the CHAMPS network (Bangladesh, Ethiopia, Kenya, Mali, Mozambique, Sierra Leone and South Africa, December 2016–December 2024). Of 18,784 eligible deaths, 8,500 (stillbirths, neonates and children under 5) had a complete investigation with minimally invasive tissue sampling, laboratory testing and verbal autopsy. Among the 3,230 neonatal deaths, complications of prematurity dominated (~40%), followed by asphyxia/hypoxia (~38%) and sepsis (~37%); gram-negative organisms were present in ~86% of neonatal deaths with an identified pathogen and Klebsiella pneumoniae in nearly half. 80.7% of the 7,558 deaths with a preventability assessment (all ages, including stillbirths) were judged preventable or possibly preventable; 44% of neonatal deaths had two or more concurrent causes.
Why it matters: This is the largest study of causes of death with pathological confirmation in low- and middle-income countries, but the catchment areas are not nationally representative, hospital deaths are overrepresented, and "preventability" is an expert judgment. The burden of perinatal asphyxia and multidrug-resistant gram-negative sepsis is directly transferable to the discussion on neonatal resuscitation and empiric antibiotic policy in Dominican units.
Source: https://doi.org/10.15585/mmwr.ss7506a1

Infectious disease, vaccines and emergency care

2. AAP expands RSV immunization criteria for the second season (8 to 19 months)

[Guideline] [United States; AAP, Pediatrics]
Policy statement from the Committee on Infectious Diseases published September 2 in Pediatrics. Immunization (nirsevimab or clesrovimab) remains recommended for all infants under 8 months who are born into or entering their first season, unless protected by documented maternal vaccination. For the 2026-2027 season, the following are added to the high-risk criteria for ages 8 to 19 months: prematurity <32 weeks regardless of support, hemodynamically significant congenital heart disease, anatomic pulmonary abnormalities or neuromuscular disorders, and Down syndrome or other chromosomal differences. Nirsevimab is the only product indicated in the second season.
Why it matters: The expanded criteria rely more on epidemiological risk than on subgroup-specific trials. In the Dominican Republic, where neither nirsevimab nor clesrovimab is in the public schedule, the value lies in guiding private prescribing and prioritizing infants born <32 weeks and those with heart disease.
Source: https://www.aap.org/en/news-room/news-releases/aap/2026/american-academy-of-pediatrics-issues-recommendations-for-rsv-immunizations-2026-2027/

3. Measles in the Americas: 52,676 confirmed cases and 61 deaths through September 5

[Epidemiology] [Region of the Americas; PAHO]
PAHO situation report No. 11 (September 11; epidemiological weeks 1–35) tallies 52,676 confirmed cases in 17 countries and territories, 3.8 times more than the same period in 2025, with 61 deaths (Guatemala 41, Mexico 19, Bolivia 1). Guatemala has accumulated 33,334 cases, Mexico 12,848, the United States 3,134, Peru 1,997 and Canada 1,119 (99.5% of the total). In weeks 33–34, 911 new cases were reported in six countries, 36.6% fewer than in the previous two weeks.
Why it matters: The recent trend is downward, but the magnitude calls for strict surveillance of fever with rash and verification of two doses of MMR at every clinical encounter; the country does not appear among the most affected in the summary, but the risk of importation through tourism and migration is high.
Source: https://www.paho.org/en/documents/situation-report-11-measles-americas-region-11-september-2026

4. 2026-2027 COVID-19 vaccine: AAP recommends universal dosing from 6 to 23 months and risk-based dosing from 2 to 18 years

[Guideline] [United States; AAP, Pediatrics]
Policy statement and technical report published in Pediatrics on September 2. Recommends universal vaccination from 6 to 23 months; from 2 to 18 years, a single dose for children at increased risk of severe disease, regardless of prior vaccination, and available at parental request for others.
Why it matters: The AAP explicitly diverges from the recent federal US schedule; the effectiveness evidence is observational. For the Dominican context, where the pediatric COVID vaccine has limited availability, this serves as a technical reference for risk groups.
Source: https://doi.org/10.1542/peds.2026-079045
https://www.aap.org/en/news-room/news-releases/aap/2026/american-academy-of-pediatrics-issues-recommendations-for-rsv-immunizations-2026-2027/

General pediatrics, growth and development

5. Weekly semaglutide in children aged 6 to 11 with obesity: 40.4% exit the obesity range (STEP Young, preliminary results)

[Industry] [Denmark; multinational trial, Novo Nordisk]
Novo Nordisk announcement of September 7 on the phase 3 STEP Young trial: 165 children aged 6 to <12 with obesity (more than 85% with class II or III obesity), randomized to weekly subcutaneous semaglutide (maximum dose 1.7 or 2.4 mg depending on baseline weight) or placebo, both with a hypocaloric diet and physical activity, for 68 weeks. The primary endpoint (percentage change in BMI) was met, with no figures published; on the confirmatory secondary endpoint, 40.4% of treated children had a BMI below the 95th percentile at 68 weeks versus 0% with placebo. Safety was described as consistent with prior studies, with no signals regarding growth or puberty.
Why it matters: This is a preliminary results announcement without peer review, without the magnitude of the primary endpoint or adverse event data, and the "on-product" estimand assumes full adherence; full data will be presented at ObesityWeek (November 14–17). It extends to school-age children evidence already established in adolescents, but long-term safety regarding growth and pubertal development remains unresolved, and cost puts it out of reach for most Dominican families.
Source: https://www.globenewswire.com/news-release/2026/09/07/3357042/0/en/novo-nordisk-step-young-phase-3-data-40-4-of-children-living-with-obesity-achieved-a-bmi-below-the-obesity-threshold-with-semaglutide-and-lifestyle-modification.html

6. Vosoritide improves growth velocity in hypochondroplasia: phase 3 CANOPY-HCH-3 trial

[Clinical trial] [NEJM Evidence, sponsored by BioMarin]
Published September 9 in NEJM Evidence and presented at ESPE 2026: a 52-week, placebo-controlled phase 3 trial in children with hypochondroplasia. A total of 81 participants were randomized: 41 to daily subcutaneous vosoritide and 40 to placebo. The change in annualized growth velocity was +1.95 cm/year with vosoritide versus −0.39 cm/year with placebo (difference 2.33 cm/year; 95% CI 1.85–2.82; p<0.0001); according to BioMarin's press release, standing height was 2.35 cm greater and height Z-score improved by 0.39. At least one adverse event occurred in 87.8% with vosoritide and 72.5% with placebo, with no grade 3 or higher events, discontinuations due to adverse events, or deaths.
Why it matters: This is a one-year, manufacturer-sponsored trial with a surrogate endpoint (growth velocity, not adult height). The indication-expansion application is already before the FDA; access to vosoritide is exceptional in our setting.
Source: https://doi.org/10.1056/EVIDoa2600257
https://www.biomarin.com/news/press-releases/biomarin-announces-positive-results-of-phase-3-voxzogo-vosoritide-study-in-hypochondroplasia-published-in-nejm-evidence/

7. FDA approves apitegromab (Isembyld), first muscle-directed drug for spinal muscular atrophy

[FDA regulatory] [United States; Scholar Rock]
Approval on September 11 for patients aged 2 years or older with SMA already receiving SMN2-directed treatment (nusinersen or risdiplam). Basis: the SAPPHIRE trial (NCT05156320), 52 weeks, 188 non-ambulatory patients aged 2 to 21, with the primary analysis in 156 patients aged 2 to 12. With 10 mg/kg IV every 4 weeks, the HFMSE scale improved by 2.2 points versus placebo (nominal p 0.0121); 34.2% achieved an improvement of ≥3 points versus 13.5% with placebo. Adverse events: respiratory infections, vomiting, headache, and increased fracture risk.
Why it matters: This is an add-on, not a replacement, treatment with a modest but clinically measurable effect in patients who kept losing function despite background therapy; fracture risk and cost are the practical limitations.
Source: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy

8. First gene therapy for Sanfilippo syndrome type A (MPS IIIA): FDA approves Fayuvi

[FDA regulatory] [United States; Ultragenyx]
On September 17, the FDA approved rebisufligene etisparvovec (Fayuvi), a single-dose intravenous AAV9 gene therapy delivering the SGSH gene. Approval is based on an open-label, single-arm, multicenter study in children aged 2 to 5 whose treated patients maintained or improved cognitive function compared with an untreated historical cohort. Adverse events >5%: elevated transaminases, nausea and vomiting, fever, cytopenias; warnings for thrombotic microangiopathy and a theoretical risk of genomic integration; requires corticosteroids starting the day before and for at least 8 weeks.
Why it matters: This is the first therapeutic option in a lethal neurodegenerative disease, but the evidence is single-arm with a historical control and no effect figures given in the FDA announcement; long-term safety follow-up is mandatory.
Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type

9. Pegcetacoplan reduces proteinuria 75% in adolescents with C3 glomerulopathy and IC-MPGN (VALIANT trial subgroup)

[Publication] [United States; CJASN, subanalysis released by Biogen]
Prespecified adolescent subgroup of the phase 3 VALIANT trial (NCT05067127; total n 124, age ≥12, biopsy-confirmed C3G or primary IC-MPGN), published in the Clinical Journal of the American Society of Nephrology and released September 17. In 55 adolescents, twice-weekly subcutaneous pegcetacoplan reduced proteinuria 75% versus placebo at 26 weeks (95% CI 59–84%; nominal p<0.001); 71% versus 4% achieved a ≥50% reduction, and 57% versus 4% achieved the composite of stable renal function with ≥50% reduction.
Why it matters: This is an underpowered subgroup with nominal p-values; even so, it is among the few randomized data points in pediatric nephrology this year and supports the indication already approved from age 12. It requires vaccination against encapsulated organisms because of meningococcal infection risk.
Source: https://investors.biogen.com/news-releases/news-release-details/phase-3-pediatric-empaveli-data-published-clinical-journal

Pediatric surgery and surgical subspecialties

10. FDA Pediatric Advisory Committee (September 16): safety review of scoliosis devices, the Contegra conduit and Epicel, and of pediatric-use drugs

[FDA regulatory] [United States]
The meeting reviewed annual reports for devices with a humanitarian device exemption used in pediatric surgery: The Tether (vertebral body tethering for idiopathic scoliosis), the Reflect Scoliosis Correction System, MID-C, the Contegra pulmonary valved conduit, Epicel cultured epidermal autografts for burns, Enterra, Liposorber and Sonalleve MR-HIFU; and postmarketing pediatric safety of remdesivir, ophthalmic atropine, dalbavancin, dasatinib, atezolizumab, intranasal naloxone and others. The published material is surveillance documentation, with no new efficacy data.
Why it matters: There are no new verifiable surgical trials in the past month (recent RCTs on ERAS in complicated appendicitis in Mexico and on nonoperative treatment of simple appendicitis are from April and earlier months, already covered). The FDA's agenda is useful for those using The Tether or Contegra: it is worth reviewing the adverse event reports published on that page.
Source: https://www.fda.gov/advisory-committees/pediatric-advisory-committee/briefing-materials-september-16-2026-meeting-pediatric-advisory-committee

Cross-cutting: regional child health and events

11. Dominican epidemiological snapshot 2026 (SINAVE, through week 29): dengue and leptospirosis rise, malaria and infant mortality fall

[Epidemiology] [Dominican Republic; SINAVE via Hoy] [Outside the period: August 16]
According to reports from the National Epidemiological Surveillance System through epidemiological week 29 (published August 16): dengue 213 confirmed cases versus 173 in 2025 (+20%, with greater burden in Santo Domingo and the endemic corridor in the security zone); malaria 115 versus 673 (−83%, foci in Azua and San Juan); leptospirosis 253 versus 85 (+190%, led by Puerto Plata); pertussis 7 cases versus 1; tetanus 16 cases and 6 deaths; infant mortality 992 versus 1,093 (−9.2%), mostly neonatal; case fatality of severe acute respiratory infection rose from 0.7 to 3.7 per 100 cases.
Why it matters: This is administrative surveillance data, not a study, and 33 days old, but it is the only recent national snapshot: the upturn in pertussis and leptospirosis and the case fatality of severe ARI are signals to reinforce pentavalent/DPT vaccination and clinical suspicion in the febrile child.

https://hoy.com.do/el-pais/republica-dominicana-reduce-malaria-colera-suben-infecciones-respiratorias-graves_1098696.html

12. Riyadh hosted the 24th International Neonatology Congress of the Saudi Neonatology Society (September 15–17)

[Congress] [Saudi Arabia]
The Saudi Neonatology Society held its 24th international congress in Riyadh from September 15 to 17, with local and international speakers, sessions and workshops; press coverage does not detail results of studies presented.
Why it matters: Included as a reference to regional scientific activity; there is no verifiable clinical data in the source. (Source in Arabic)
Source: https://sabq.org/article/d8212yo

Upcoming meetings and dates

AAP National Conference & Exhibition 2026, San Diego, October 2–6, 2026 (http://aapexperience.org).
ObesityWeek 2026, Washington DC, November 14–17: presentation of the full STEP Young results (semaglutide in children aged 6 to 11).

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.